Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.89 |
| ▸ | HTT | P42858 | 1/20 | 0.89 |
| ▸ | CHKA | P35790 | 3/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28192273 | 0.96 | ALDH1A1 (0.96) | ALDH1A1HTTCHKAHRH3SMN1; SMN2 | |
| SCHEMBL13293320 | 0.94 | ALDH1A1 (1.00) | ALDH1A1HTTHRH3SMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL7401709 | 0.92 | ALDH1A1 (0.96) | ALDH1A1HTTHRH3SMN1; SMN2KDM4E | |
| SCHEMBL4033896 | 0.85 | ALDH1A1 (0.71) | ALDH1A1HTTCHKASMN1; SMN2KDM4E | |
| SCHEMBL16226262 | 0.85 | ALDH1A1 (0.71) | ALDH1A1HTTCHKAKDM4EDRD4 | |
| SCHEMBL2921989 | 0.83 | ALDH1A1 (0.69) | ALDH1A1HTTHRH3KDM4ESIGMAR1 | |
| SCHEMBL12891510 | 0.83 | ALDH1A1 (0.69) | ALDH1A1HTTCHKAKDM4E | |
| SCHEMBL30334972 | 0.83 | ALDH1A1 (0.64) | ALDH1A1HTTCHKAHRH3SMN1; SMN2 | |
| SCHEMBL3125832 | 0.83 | ALDH1A1 (0.69) | ALDH1A1HTTCHKASMN1; SMN2KDM4E | |
| SCHEMBL16226483 | 0.83 | ALDH1A1 (0.69) | ALDH1A1HTTPOLBSIGMAR1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253676-A1 | Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253676-A1 | Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes | GRK4, GRK5, GRK2 | ALDH1A1 3361/4885HTT 3505/4885CHKA 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.